←Back to list

Sword Health

Developer of an artificial intelligence-powered digital therapeutic system designed to aid with musculoskeletal healthca
Developer of an artificial intelligence-powered digital therapeutic system designed to aid with musculoskeletal healthcare needs.
Clinics/Outpatient Services 📍 New York, NY Founded 2014
Current Valuation
$4.5B
as of 2025-Q2
UNICORN

QL Price

$2.9B
-35% vs last round
QuantLogix's current estimate for Sword Health, published 2026-09-27 — below the last disclosed round of $4.5B (2025-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $4.5B 2025-Q2 weight 0.42
Secondary market print $1.8B 2026-06-27 weight 0.58
How this price has held up
No round has priced for Sword Health since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to Sword Health →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Sword Health, 2026-09-27 (2768d356676feeaa). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is Sword Health going public?
No. Sword Health is private and has not filed to go public. There is no S-1 on file.
What is Sword Health's valuation in 2026?
Sword Health is valued at $4.5B as of 2025-Q2, set by its Series F ($39.84M, Jun 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Sword Health filed an S-1?
No public S-1 is on file for Sword Health.
How much has Sword Health raised?
Sword Health has raised $493.52M in total, most recently a Series F of $39.84M in Jun 2025.
Is Sword Health publicly traded — can you buy Sword Health stock?
No. Sword Health is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Sword Health on its Pre-IPO Access Desk.
How to actually get exposure to Sword Health →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

Founded
2014
HQ
New York, NY
Employees
1,000
Total Raised
$493.52M
Last Round
Series F — $39.84M (Jun 2025)
IPO Status
private

Fundraising Status

Series F · $39.84M · 1y 3mo ago
privateTotal raised $493.52M

Secondary Market

Implied price / share
$27.83
Last round price / share
$71.51
vs last round
-61.1%
Open interest
2
Last round price vs secondary price
Last round vs current secondary price per share$71.51Last round$27.83Current
Secondary price return by period
Secondary market period returns3-month+25.1%6-month+44.9%1-year+20.7%All-time+85.5%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series F$39.84MJun 2025—$4.5B

Vertical Intelligence — Biotech / Gene Therapy

Registered trials
15
5 active · 0 recruiting
Focus areas
Musculoskeletal Diseases
Knee Osteoarthritis · Hip Osteoarthritis
Latest trial start
2025-09-09
Name-verified against lead sponsor "Sword Health, SA" on ClinicalTrials.gov as of 2026-09-27. Verify on ClinicalTrials.gov ↗

Talent Signal

Hiring trend
▲ Hiring uptrend
+28% vs 2026-08
Open roles
32
via greenhouse
Product-build share
44%
engineering, research, product, design
Trajectory
expanding
balanced build + GTM — 44% builders vs 56% go-to-market/G&A — scaling both sides.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by month25Aug '2632Sep '26
Open roles by function
Open roles by functionSales & GTM8Marketing5Engineering5Other4Product3Data & ML3Security2Support1Clinical & Science1
■ product-building   ■ go-to-market / G&A
Head of Clinical Development - PulseHead of Product, PulseSecurity Operations Lead (SecOps)Senior AI Engineer (Greek speaking)Senior Android Engineer - Consumer GrowthSenior Backend Engineer - Consumer Growth
Counted from Sword Health's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
MedicalHealth CareTherapeuticsmHealth
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.